Pier Capital Boosts Stake in Capricor Therapeutics

Biotechnology firm sees increased institutional investment as it advances pipeline

Mar. 13, 2026 at 10:39am

Got story updates? Submit your updates here. ›

Pier Capital LLC, a hedge fund, increased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 35% during the third quarter of 2026, according to a recent SEC filing. Capricor is a clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases.

Why it matters

The increased investment from Pier Capital signals growing institutional interest in Capricor as the company advances its pipeline of promising therapeutic candidates, including its lead product CAP-1002 which is being evaluated for Duchenne muscular dystrophy and COVID-19-related heart injury.

The details

According to the 13F filing, Pier Capital now owns approximately 496,554 shares of Capricor, representing around 1.09% of the company's outstanding stock. This marks a 35% increase in the fund's position compared to the prior quarter. Capricor is developing a range of cell and exosome-based therapies, with a focus on addressing conditions characterized by inflammation, fibrosis, and tissue degeneration.

  • Pier Capital increased its Capricor holdings by 35% in the 3rd quarter of 2026.

The players

Pier Capital LLC

A hedge fund that increased its investment in Capricor Therapeutics by 35% in Q3 2026.

Capricor Therapeutics, Inc.

A clinical-stage biotechnology company focused on developing cell and exosome-based therapies for cardiovascular and rare diseases.

Got photos? Submit your photos here. ›

The takeaway

Capricor's growing institutional investor base signals confidence in the company's pipeline of innovative cell and exosome-based therapies targeting serious medical conditions. As Capricor continues to advance its research, the increased investment from funds like Pier Capital could help fuel further development and commercialization efforts.